Author:
Si Lu,Zhang Xiaoshi,Shu Yongqian,Pan Hongming,Wu Di,Liu Jiwei,Lou Fang,Mao Lili,Wang Xuan,Wen Xizhi,Gu Yanhong,Zhu Lingjun,Lan Shijie,Cai Xin,Diede Scott J.,Zhou Yu,Ge Jun,Li Jianfeng,Wu Haiyan,Guo Jun
Funder
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp
Reference28 articles.
1. Guo J, Qin S, Liang J, Lin T, Si L, Chen X, et al. Chinese guidelines on the diagnosis and treatment of melanoma (2015 ed). Ann Transl Med 2015;3:322.
2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010
3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011
4. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study;Robert;Lancet Oncol,2013
5. Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules;Robert;Ann Oncol,2014
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献